课题基金 / 基金详情

项目摘要

项目成果

ROSALYN D BLUMENTHAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Core C is the animal core. The core will provide technical service to preclinical projects 1, and 2 establishing subcutaneous and systemic tumor models, assessing uptake of radiolabeled agents, determining therapeutic efficacy of radiolabeled antibody conjugates and haptens, and identifying toxicity associated with single and multimodal treatment protocols. It will also collect blood for toxicity assessments and tissue for the histological analysis .by Core E. It will use 2 F/T technicians to manage 2160-2560 mice per year in its AAALAC-accredited facility. Specifically it will be responsible for the following tasks: (a) developing new tumor models in untreated and immunosuppressed mice, (b) injecting cultured tumor cells intravenously or subcutaneously in SCID mice or nude mice, (c) dosing animals with appropriate therapeutic agents [e.g., bispecific antibodies, radiolabeled haptens, radioantibodies, naked antibodies, and chemotherapeutics], (d) monitoring survival, body weight changes and onset of hind-leg paralysis in systemic tumor models and measuring tumor size of subcutaneous tumors by 3D caliper measurements, (e) performing biodistribution studies, (f) providing fixed samples of tumors and tissues for histology to monitor viability and to monitor expression of antigens by immunohistology and for microautoradiography studies, (g) collecting blood samples for white blood cell and platelet enumeration and for measurement of cardiac troponin in project 4, (h) entering all data (biodistribution, therapy, WBC/Plt, body weight) into Excel spreadsheets, and (i) setting up immunoscintigraphy studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chronobiological Principles to Maximize Efficacy of Alt*
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
PRE-CLINICAL COMBINATION CHEMO/RADIOANTIBODY THERAPY
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
海外基金